Global drug firm Mylan offers about $30bn to buy Ireland-based Perrigo
April 9 , 2015
Global drug company Mylan is offering to buy Perrigo for almost $30 billion in what would be a cash-and-stock deal.
Perrigo, an Ireland based drugs firm, has confirmed the move.
Robert Coury, the executive chairman of Mylan, said that such an agreement would deliver “value to shareholders and other stakeholders” of both firms.
If the deal is completed, it will create a firm with a potential stock market value of around $60 billion, analysts believe.